Why the study?
As the number of patients with both cancer and cardiovascular diseases continues to rise, cardiotoxicity from anti-cancer therapies has become a frequent problem requiring current perspectives and close interdisciplinary cooperation.
This review highlights the growing importance of cardio-oncology and the need for regular cardiovascular monitoring and collaboration between cardiologists and oncologists during anti-cancer treatment.
Answers are grounded in this paper and cite their sources.
Supports integrated cardio-oncology care during cancer therapy; leaves open optimal monitoring protocols for prospective trials.
Cardiovascular (CV) diseases and cancer are the leading causes of death in Europe and the United States. Both diseases have extensive overlap and share common risk factors, symptoms, and outcomes. As the number of patients with both cancer and CV diseases continues to rise, the field of cardio-oncology is gaining increased attention. A frequent problem during anti-cancer treatment is cardiotoxicity caused by the side-effects of chemo-, immuno-, targeted, and radiation therapies. This problem may manifest as acute coronary syndrome, myocarditis, arrhythmias, or heart failure. Modern cardio-oncology spans many different research areas. While some researchers focus on treating patients that have already developed cardiotoxicity, others aim to identify new methods for preventing cardiotoxicity before, during, and after anti-cancer therapy. Both groups share the common understanding that regular monitoring of cancer patients is the basis for optimal medical treatment. Optimal treatment can only be achieved through close cooperation between cardiologists and oncologists. This review summarizes the current views on cardio-oncology and discusses the cardiotoxicities associated with commonly used chemotherapeutics.
No takes yet. Share an insight, caveat, or question.
Bohdan et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: